Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
471 results about "Immunoconjugate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunoconjugates are antibodies conjugated (joined) to a second molecule, usually a toxin, radioisotope or label. These conjugates are used in immunotherapy and to develop monoclonal antibody therapy as a targeted form of chemotherapy when they are often known as antibody-drug conjugates.
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
Owner:IMMUNOGEN INC
Immunoconjugates with an intracellularly-cleavable linkage
InactiveUS7999083B2Reducing certain severe side effectsReceive treatment wellAntibacterial agentsOrganic active ingredientsIntracellularAntibody fragments
Owner:IMMUNOMEDICS INC
Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ActiveUS20140093511A1Improve physical stabilityGood chemical stabilityImmunoglobulins against cell receptors/antigens/surface-determinantsAntiviralsLymphocyteLymphocyte activation
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011 / 0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
Owner:BRISTOL MYERS SQUIBB CO
Immunoconjugates with an Intracellularly-Cleavable Linkage
ActiveUS20100104589A1Reducing certain severe side effectsReceive treatment wellAntibacterial agentsOrganic active ingredientsAntibody fragmentsChemistry
Owner:IMMUNOMEDICS INC
Antibody methods for selectively inhibiting VEGF
InactiveUS7056509B2Inhibit bindingAntibacterial agentsSenses disorderDiseaseAngiogenesis growth factor
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Antibody kits for selectively inhibiting VEGF
InactiveUS6887468B1Reduce control antibody bindingReduce the binding forceAntibacterial agentsSenses disorderDiseaseAngiogenesis growth factor
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Anti-pd-1 antibody and use thereof
This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.
Owner:JUNMENG BIOSCIENCES CO LTD +1
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
Owner:IMMUNOGEN INC
Anti-IL-17 antibodies
Owner:ELI LILLY & CO
Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
ActiveUS20090028856A1Effectively preventingEffectively treatingOrganic active ingredientsBacteriaMammalHematopoietic Tumor
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Owner:GENENTECH INC
Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ActiveCN101213297AMicrobiological testing/measurementImmunoglobulins against cell receptors/antigens/surface-determinantsImmunotherapeutic agentProgrammed death
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Owner:ONO PHARMA CO LTD +1
Mutated anti-cd22 antibodies and immunoconjugates
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Mutant interleukin-2 polypeptides
ActiveUS20120244112A1Eliminates and decrease and delayEliminates and decrease and and and effectPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunotherapeutic agentReceptor
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:ROCHE GLYCART AG
Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
InactiveUS7541034B1Growth inhibitionBacteriaPeptide/protein ingredientsPseudomonas aeruginosa exotoxin APseudomonas
Methods and compositions relating to recombinant anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides diagnostic methods, and means to inhibit the growth of malignant B cells.
Owner:UNITED STATES OF AMERICAN AS REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES
Interferon alpha antibodies and their uses
ActiveUS20070014724A1Inhibit biological activityInhibiting surface expressionPeptide/protein ingredientsAntipyreticAutoimmune conditionAutoimmune disease
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
Owner:MEDAREX LLC
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
InactiveUS20070183971A1Inhibits and delay and prevents growth and spreadHigh non-selective cytotoxicityOrganic active ingredientsIn-vivo radioactive preparationsSyndecan 1In vivo
Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.
Owner:BIOTEST SERUM INST GMBH
Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)
InactiveUS20090297438A1Effective antibody dependent cell-mediated cytotoxicity (ADCC) of the tumorPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenProstate specific membrane
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PSMA with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancer.
Owner:MEDAREX INC
Anti-CD79B antibodies and immunoconjugates and methods of use
The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Owner:GENENTECH INC
Anti-integrin immunoconjugates, methods and uses
The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
Owner:IMMUNOGEN INC +1
Mutant interleukin-2 polypeptides
ActiveUS9266938B2Eliminates and decrease and delayEliminates and decrease and and and effectPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunotherapeutic agentNucleotide
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:ROCHE GLYCART AG
Anti-IL-17 Antibodies
ActiveUS20080269467A1Lower Level RequirementsReduced activityNervous disorderAntipyreticDiseaseAntigen Binding Fragment
Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
Owner:ELI LILLY & CO
Antibody-sn-38 immunoconjugates with a cl2a linker
ActiveUS20140227180A1Improve drug bioavailabilityGood treatment effectOrganic active ingredientsPeptide/protein ingredientsDiseaseSide effect
The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and / or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
Owner:IMMUNOMEDICS INC
Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
InactiveUS20020197262A1Good curative effectEasy to optimizeElectrotherapyHybrid immunoglobulinsAntiendomysial antibodiesOncology
The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.
Owner:THE GENERAL HOSPITAL CORP
Isolated monoclonal antibodies that specifically bind to human Claudin 18.2
ActiveCN109762067AOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsMonoclonal antibody 14G2AAntigen receptors
Owner:BEIJING MABWORKS BIOTECH
Anti-myostatin antibodies
Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.
Owner:ELI LILLY & CO
ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
InactiveUS20100260748A1Heavy metal active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesBiochemistry
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Owner:F HOFFMANN LA ROCHE & CO AG
Mutant interleukin-2 polypeptides
ActiveUS20160208017A1Eliminates and decrease and delayEliminates and decrease and and and effectPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunotherapeutic agentNucleotide
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:ROCHE GLYCART AG
Immunoconjugates
The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
Owner:ROCHE GLYCART AG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com